ATRX loss may guide targeted treatment for aggressive sarcomas
Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors.
Read original article on The Medical News →